[go: up one dir, main page]

WO2000008006A3 - Piperidine and piperazine derivatives, process for their preparation and pharmaceutical compounds containing them - Google Patents

Piperidine and piperazine derivatives, process for their preparation and pharmaceutical compounds containing them Download PDF

Info

Publication number
WO2000008006A3
WO2000008006A3 PCT/GB1999/002560 GB9902560W WO0008006A3 WO 2000008006 A3 WO2000008006 A3 WO 2000008006A3 GB 9902560 W GB9902560 W GB 9902560W WO 0008006 A3 WO0008006 A3 WO 0008006A3
Authority
WO
WIPO (PCT)
Prior art keywords
piperidine
preparation
compounds containing
pharmaceutical compounds
piperazine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1999/002560
Other languages
French (fr)
Other versions
WO2000008006A2 (en
Inventor
Stephen Richard Baker
David Bleakman
John Goldsworthy
Patric James Hahn
Gunnar Erik Jagdmann
Shelley Hunnings Turkington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co Ltd
Eli Lilly and Co
Original Assignee
Eli Lilly and Co Ltd
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co Ltd, Eli Lilly and Co filed Critical Eli Lilly and Co Ltd
Priority to EP99936874A priority Critical patent/EP1104413A2/en
Priority to AU51845/99A priority patent/AU5184599A/en
Priority to CA002305406A priority patent/CA2305406A1/en
Priority to JP2000563639A priority patent/JP2003510244A/en
Publication of WO2000008006A2 publication Critical patent/WO2000008006A2/en
Publication of WO2000008006A3 publication Critical patent/WO2000008006A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically-acceptable salt or ester thereof in which X, R?1, R2, R3, R4, R5 and R6¿ have the meanings given in the specification, is useful in the treatment of diseases of the central nervous system. The invention further relates to a compound of formula (I) or a pharmaceutically-acceptable salt or ester thereof useful in the treatment of diseases of the central nervous system.
PCT/GB1999/002560 1998-08-07 1999-08-04 Piperidine and piperazine derivatives, process for their preparation and pharmaceutical compounds containing them Ceased WO2000008006A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99936874A EP1104413A2 (en) 1998-08-07 1999-08-04 Piperidine and piperazine derivatives, process for their preparation and pharmaceutical compounds containing them
AU51845/99A AU5184599A (en) 1998-08-07 1999-08-04 Pharmaceutical compounds
CA002305406A CA2305406A1 (en) 1998-08-07 1999-08-04 Pharmaceutical compounds
JP2000563639A JP2003510244A (en) 1998-08-07 1999-08-04 Pharmaceutical compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9817197.8A GB9817197D0 (en) 1998-08-07 1998-08-07 Pharmaceutical compounds
GB9817197.8 1998-08-07

Publications (2)

Publication Number Publication Date
WO2000008006A2 WO2000008006A2 (en) 2000-02-17
WO2000008006A3 true WO2000008006A3 (en) 2000-08-03

Family

ID=10836864

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/002560 Ceased WO2000008006A2 (en) 1998-08-07 1999-08-04 Piperidine and piperazine derivatives, process for their preparation and pharmaceutical compounds containing them

Country Status (6)

Country Link
EP (1) EP1104413A2 (en)
JP (1) JP2003510244A (en)
AU (1) AU5184599A (en)
CA (1) CA2305406A1 (en)
GB (1) GB9817197D0 (en)
WO (1) WO2000008006A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1138328A1 (en) * 2000-03-29 2001-10-04 Eli Lilly And Company Limited Naphthalene derivatives as CNS drugs
WO2011000945A2 (en) * 2009-07-03 2011-01-06 Nensius Research A/S Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the cns
CN107011288B (en) * 2017-04-20 2019-03-22 齐鲁天和惠世制药有限公司 A kind of preparation method of aripiprazole intermediate 1- (2,3- dichlorophenyl) piperazine hydrochloride
WO2023172415A1 (en) * 2022-03-07 2023-09-14 Firmenich Incorporated Sweetener compositions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0072623A1 (en) * 1981-07-18 1983-02-23 Pfizer Limited Imidazole antifungal agents
US4457931A (en) * 1982-09-27 1984-07-03 Selvi & C. S.P.A. Piperazine derivatives with anticholinergic and/or antihistaminic activity
EP0395313A2 (en) * 1989-04-22 1990-10-31 American Home Products Corporation Tertiary alkyl functionalized piperazine derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0072623A1 (en) * 1981-07-18 1983-02-23 Pfizer Limited Imidazole antifungal agents
US4457931A (en) * 1982-09-27 1984-07-03 Selvi & C. S.P.A. Piperazine derivatives with anticholinergic and/or antihistaminic activity
EP0395313A2 (en) * 1989-04-22 1990-10-31 American Home Products Corporation Tertiary alkyl functionalized piperazine derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CROSS, PETER E. ET AL: "Substituted trifluoromethyl phenyl piperazines as anorectic agents", EUR. J. MED. CHEM. - CHIM. THER. (1977), 12(2), 173-6, XP002056653 *
PERRONE, R. ET AL: "Synthesis of arylpiperazines with a terminal naphthothiazole group and their evaluation on 5-HT, DA and.alpha. receptors", EUR. J. MED. CHEM. (1997), 32(9), 739-746, XP004094070 *
PERRONE, ROBERTO ET AL: "N-[2-[4-(4-Chlorophenyl)piperazin-1-yl]ethyl]-3-methoxybenzamide: A Potent and Selective Dopamine D4 Ligand", J. MED. CHEM. (1998), 41(24), 4903-4909, XP000907280 *

Also Published As

Publication number Publication date
AU5184599A (en) 2000-02-28
GB9817197D0 (en) 1998-10-07
JP2003510244A (en) 2003-03-18
WO2000008006A2 (en) 2000-02-17
EP1104413A2 (en) 2001-06-06
CA2305406A1 (en) 2000-02-17

Similar Documents

Publication Publication Date Title
AU6690686A (en) Piperdine derivative and pharmaceutical composition
RU2088589C1 (en) Derivatives of 17 beta-substituted-4-aza-5-5 alpha-androstane-3-ones, methods of synthesis of compounds, pharmaceutical composition, compound 4
MX9604020A (en) Arylalkyldiazinones.
WO1999064409A3 (en) Benzothiepine-1,1-dioxide derivatives, method for producing them, medicaments containing these compounds and their use
CA2258548A1 (en) Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
HUT68357A (en) Heterocyclic-cyclic-amine derivatives, pharmaceutical compositions containing them and process for their production
HUT71344A (en) Pharmaceutical compositions for inhibiting thrombin containing 2-phenyl-3-aroyl-benzothiophene derivatives and process for their preparation
RU94038064A (en) Derivatives of piperazine and piperidine, their use as antipsychotic agents, method of their synthesis, pharmaceutical composition
EP0807633A3 (en) Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones
HUP9802762A2 (en) Diphenylmethylene piperidine derivatives, pharmaceutical compositions containing them, process for producing them and their use
DE3572978D1 (en) Piperazine compound as paf-antagonist
ES2036926A1 (en) (2-Alkyl-3-pyridyl)methylpiperazine derivatives as PAF antagonists.
AU7581394A (en) Galanthamine derivatives, a process for their preparation and their use as medicaments
CA2094703A1 (en) Substituted piperazines as central nervous system agents
IL136100A (en) Biphenylamidine derivatives and pharmaceutical compositions containing the same
AU672644B2 (en) Aryl substituted heterocyclic compounds
WO2000008006A3 (en) Piperidine and piperazine derivatives, process for their preparation and pharmaceutical compounds containing them
AU671163B2 (en) Alkyl substituted heterocyclic compounds
GR3017348T3 (en) Novel isoindolinone derivative, preparation thereof, and pharmaceutical compositions containing same.
AP9801417A0 (en) Piperidine acetic acid derivatives and their use in the treatment of thrombotic disorders.
MY106235A (en) New 2 - carbonyl substituted n, n'' -di (trimethoxybenzoyl) piperazines, process for preparing the same and therapeutical compounds containing them.
HK47492A (en) Piperazine derivatives
UA27738C2 (en) 2,3,4,5,6,7-hexahydro-1-(4-(1-(4-(2-methoxyphenyl)piperazinyl))-2-phenylbutyryl)-1h-azepine or pharmaceutically acceptable acid addition salt thereof capable of binding to 5-ht receptors, processes for their preparation (variants) and pharmaceutical composition
CA2180660A1 (en) Novel piperidine derivatives with paf antagonist activity
CA2189567A1 (en) Substituted fused and bridged bicyclic compounds as therapeutic agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999936874

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2305406

Country of ref document: CA

Ref country code: CA

Ref document number: 2305406

Kind code of ref document: A

Format of ref document f/p: F

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 09509980

Country of ref document: US

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 1999936874

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999936874

Country of ref document: EP